HCA Healthcare Zukünftiges Wachstum
Future Kriterienprüfungen 2/6
HCA Healthcare wird ein jährliches Gewinn- und Umsatzwachstum von 5.8% bzw. 5.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 113.1% betragen.
Wichtige Informationen
5.8%
Wachstumsrate der Gewinne
9.4%
EPS-Wachstumsrate
| Healthcare Gewinnwachstum | 21.0% |
| Wachstumsrate der Einnahmen | 5.5% |
| Zukünftige Eigenkapitalrendite | 113.1% |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 08 Nov 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Results: HCA Healthcare, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Jul 26
HCA Healthcare, Inc. Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next
Apr 30HCA Healthcare, Inc. (NYSE:HCA) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 02Recent updates
Shareholders Would Enjoy A Repeat Of HCA Healthcare's (NYSE:HCA) Recent Growth In Returns
Nov 10HCA Healthcare Q3 Earnings Preview: Step Change In Value (Rating Upgrade)
Oct 22HCA Healthcare, Inc. (NYSE:HCA) Not Lagging Market On Growth Or Pricing
Oct 16HCA Healthcare, Inc.'s (NYSE:HCA) Intrinsic Value Is Potentially 63% Above Its Share Price
Oct 01HCA Healthcare: Still A Great Play On Long-Term Growth And Valuation
Sep 28Is It Too Late To Consider Buying HCA Healthcare, Inc. (NYSE:HCA)?
Sep 16Does HCA Healthcare (NYSE:HCA) Have A Healthy Balance Sheet?
Sep 01Results: HCA Healthcare, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Jul 26Are Investors Undervaluing HCA Healthcare, Inc. (NYSE:HCA) By 27%?
Jun 21HCA Healthcare, Inc.'s (NYSE:HCA) P/E Still Appears To Be Reasonable
Jun 06Is It Too Late To Consider Buying HCA Healthcare, Inc. (NYSE:HCA)?
May 21HCA Healthcare, Inc. Just Beat EPS By 16%: Here's What Analysts Think Will Happen Next
Apr 30Capital Investment Trends At HCA Healthcare (NYSE:HCA) Look Strong
Apr 11HCA Healthcare Is Finally At Fair Value (Rating Downgrade)
Mar 19HCA Healthcare: Improving Margins Now Reflected In Shares (Rating Downgrade)
Feb 29HCA Healthcare (NYSE:HCA) Is Increasing Its Dividend To $0.66
Feb 25HCA Healthcare (NYSE:HCA) Is Paying Out A Larger Dividend Than Last Year
Feb 05HCA Healthcare, Inc. (NYSE:HCA) Analysts Are Pretty Bullish On The Stock After Recent Results
Feb 02HCA Healthcare, Inc. (NYSE:HCA) Shares Could Be 40% Below Their Intrinsic Value Estimate
Jan 21At US$276, Is HCA Healthcare, Inc. (NYSE:HCA) Worth Looking At Closely?
Jan 08HCA Healthcare, Inc.'s (NYSE:HCA) Share Price Is Matching Sentiment Around Its Earnings
Dec 25HCA Healthcare Continues To Impress
Dec 14Should You Be Adding HCA Healthcare (NYSE:HCA) To Your Watchlist Today?
Dec 11HCA Remains Attractive Despite A JV Misstep
Nov 20These 4 Measures Indicate That HCA Healthcare (NYSE:HCA) Is Using Debt Extensively
Oct 26HCA Healthcare: Rx For Success
Oct 10A Look Into HCA Healthcare's (NYSE:HCA) Impressive Returns On Capital
Oct 09HCA Healthcare: Impact Of Medicare Advantage Growth And Demographic Shift
Sep 30At US$256, Is It Time To Put HCA Healthcare, Inc. (NYSE:HCA) On Your Watch List?
Sep 17HCA Healthcare Is Beating The Industry
Sep 13Here's Why HCA Healthcare (NYSE:HCA) Can Manage Its Debt Responsibly
Jul 25HCA Healthcare (NYSE:HCA) Is Aiming To Keep Up Its Impressive Returns
Jul 10HCA Healthcare's Service Optimization And Capabilities Support Long-Run Growth
Jul 03HCA Healthcare, Inc.'s (NYSE:HCA) Intrinsic Value Is Potentially 45% Above Its Share Price
Jun 25Is Now The Time To Look At Buying HCA Healthcare, Inc. (NYSE:HCA)?
Jun 09HCA Healthcare's (NYSE:HCA) Shareholders Will Receive A Bigger Dividend Than Last Year
Jun 09HCA Healthcare (NYSE:HCA) Has Announced That It Will Be Increasing Its Dividend To $0.60
May 25HCA Healthcare (NYSE:HCA) Has A Pretty Healthy Balance Sheet
Apr 22HCA Healthcare (NYSE:HCA) Knows How To Allocate Capital
Apr 04Are Investors Undervaluing HCA Healthcare, Inc. (NYSE:HCA) By 45%?
Mar 16At US$249, Is HCA Healthcare, Inc. (NYSE:HCA) Worth Looking At Closely?
Feb 26Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 78,657 | 6,661 | 5,173 | 10,848 | 20 |
| 12/31/2025 | 74,695 | 6,216 | 4,764 | 10,280 | 22 |
| 12/31/2024 | 70,586 | 5,831 | 5,245 | 10,159 | 21 |
| 9/30/2024 | 69,621 | 5,929 | 5,880 | 10,629 | N/A |
| 6/30/2024 | 68,347 | 5,738 | 4,888 | 9,593 | N/A |
| 3/31/2024 | 66,716 | 5,470 | 5,432 | 10,097 | N/A |
| 12/31/2023 | 64,968 | 5,242 | 4,687 | 9,431 | N/A |
| 9/30/2023 | 63,162 | 5,716 | 4,376 | 9,284 | N/A |
| 6/30/2023 | 61,920 | 5,771 | 4,933 | 9,825 | N/A |
| 3/31/2023 | 60,879 | 5,733 | 4,249 | 8,980 | N/A |
| 12/31/2022 | 60,233 | 5,643 | 4,127 | 8,522 | N/A |
| 9/30/2022 | 59,800 | 5,376 | 4,174 | 8,438 | N/A |
| 6/30/2022 | 60,105 | 6,511 | 3,673 | 7,695 | N/A |
| 3/31/2022 | 59,720 | 6,806 | 4,532 | 8,316 | N/A |
| 12/31/2021 | 58,752 | 6,956 | 5,382 | 8,959 | N/A |
| 9/30/2021 | 57,981 | 6,568 | -200 | 2,933 | N/A |
| 6/30/2021 | 56,016 | 4,967 | 640 | 3,373 | N/A |
| 3/31/2021 | 52,649 | 4,596 | 7,209 | 9,845 | N/A |
| 12/31/2020 | 51,533 | 3,754 | 6,397 | 9,232 | N/A |
| 9/30/2020 | 50,763 | 3,399 | 11,959 | 15,320 | N/A |
| 6/30/2020 | 50,146 | 3,343 | 10,718 | 14,729 | N/A |
| 3/31/2020 | 51,680 | 3,047 | 3,773 | 8,003 | N/A |
| 12/31/2019 | 51,336 | 3,505 | 3,444 | 7,602 | N/A |
| 9/30/2019 | 50,087 | 3,498 | 3,235 | 7,272 | N/A |
| 6/30/2019 | 48,844 | 3,645 | 3,123 | 6,867 | N/A |
| 3/31/2019 | 47,771 | 3,682 | 2,792 | 6,452 | N/A |
| 12/31/2018 | 46,677 | 3,787 | 3,188 | 6,761 | N/A |
| 9/30/2018 | 45,965 | 3,197 | 2,918 | 6,320 | N/A |
| 6/30/2018 | 45,210 | 2,864 | N/A | 5,607 | N/A |
| 3/31/2018 | 44,414 | 2,701 | N/A | 5,429 | N/A |
| 12/31/2017 | 43,614 | 2,216 | N/A | 5,426 | N/A |
| 9/30/2017 | 42,693 | 2,662 | N/A | 5,391 | N/A |
| 6/30/2017 | 42,267 | 2,854 | N/A | 5,589 | N/A |
| 3/31/2017 | 41,853 | 2,855 | N/A | 5,534 | N/A |
| 12/31/2016 | 41,490 | 2,890 | N/A | 5,653 | N/A |
| 9/30/2016 | 41,098 | 2,552 | N/A | 5,512 | N/A |
| 6/30/2016 | 40,684 | 2,383 | N/A | 5,407 | N/A |
| 3/31/2016 | 40,262 | 2,232 | N/A | 5,115 | N/A |
| 12/31/2015 | 39,678 | 2,129 | N/A | 4,734 | N/A |
| 9/30/2015 | 39,065 | 2,074 | N/A | 4,803 | N/A |
| 6/30/2015 | 38,429 | 2,143 | N/A | 4,830 | N/A |
| 3/31/2015 | 37,762 | 2,119 | N/A | 5,023 | N/A |
| 12/31/2014 | 36,918 | 1,875 | N/A | 4,448 | N/A |
| 9/30/2014 | 36,118 | 1,772 | N/A | 4,047 | N/A |
| 6/30/2014 | 35,354 | 1,619 | N/A | 3,819 | N/A |
| 3/31/2014 | 34,574 | 1,559 | N/A | 3,383 | N/A |
| 12/31/2013 | 34,182 | 1,556 | N/A | 3,680 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: HCADas prognostizierte Gewinnwachstum (5.8% pro Jahr) liegt über der Sparquote (2.6%).
Ertrag vs. Markt: HCADie Erträge des Unternehmens (5.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.4% pro Jahr).
Hohe Wachstumserträge: HCADie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.
Einnahmen vs. Markt: HCADie Einnahmen des Unternehmens (5.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (9% pro Jahr).
Hohe Wachstumseinnahmen: HCADie Einnahmen des Unternehmens (5.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: HCADie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (113.1%).